The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulent M.tb in a ‘challenge’ experiment following vacci...
Principais autores: | Tanner, R, Hoogkamer, E, Bitencourt, J, White, A, Boot, C, Sombroek, CC, Harris, SA, O'Shea, MK, Wright, D, Wittenberg, R, Sarfas, C, Satti, I, Verreck, FAW, Sharpe, SA, Fletcher, HA, McShane, H |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
F1000Research
2021
|
Registros relacionados
-
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, R, et al.
Publicado em: (2021) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 2; peer review: 2 approved]
por: Rachel Tanner, et al.
Publicado em: (2021-09-01) -
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Rachel Tanner, et al.
Publicado em: (2021-01-01) -
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
por: Pepponi, I, et al.
Publicado em: (2017) -
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
por: Brennan, M, et al.
Publicado em: (2017)